[HTML][HTML] Neutralizing antibodies for the prevention and treatment of COVID-19
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …
[HTML][HTML] Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
[HTML][HTML] Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …
developed as therapeutics and are a major contributor to neutralizing antibody responses …
[HTML][HTML] Infection-and vaccine-induced antibody binding and neutralization of the B. 1.351 SARS-CoV-2 variant
VV Edara, C Norwood, K Floyd, L Lai… - Cell host & …, 2021 - cell.com
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …
[HTML][HTML] The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Neutralizing antibodies (nAbs) elicited against the receptor binding site (RBS) of the spike
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …
[HTML][HTML] An engineered bispecific human monoclonal antibody against SARS-CoV-2
Z Li, S Li, G Zhang, W Peng, Z Chang, X Zhang… - Nature …, 2022 - nature.com
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
SARS-CoV-2 and SARS-CoV spike-RBD structure and receptor binding comparison and potential implications on neutralizing antibody and vaccine development
C Sun, L Chen, J Yang, C Luo, Y Zhang, J Li, J Yang… - Biorxiv, 2020 - biorxiv.org
Abstract SARS-CoV-2 and SARS-CoV share a common human receptor ACE2. Protein-
protein interaction structure modeling indicates that spike-RBD of the two viruses also has …
protein interaction structure modeling indicates that spike-RBD of the two viruses also has …
[HTML][HTML] A potently neutralizing antibody protects mice against SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions
of infections and hundreds of thousands of deaths globally. There are no widely available …
of infections and hundreds of thousands of deaths globally. There are no widely available …
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
AL Cathcart, C Havenar-Daughton, FA Lempp, D Ma… - biorxiv, 2021 - biorxiv.org
ABSTRACT VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs)
targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS …
targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS …